Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Allergan profiles its Ocular Hypotensive Lipids at SOE 1999

Aug. 3, 1999

Alcon describes therapeutic potential of ocular antiinflammatory agents

Aug. 3, 1999

Acadia licenses novel leads for glaucoma therapy to Allergan

July 30, 1999

New muscarinic compounds from Alcon especially useful for Rx of glaucoma

July 29, 1999

New agents for glaucoma disclosed by Alcon in recent patent literature

July 27, 1999

Sunrise LTK System not recommended for FDA approval

July 26, 1999

Alcon's new prostaglandin analogues for glaucoma

July 26, 1999

FDA Advisory Committee votes against recommending Allergan therapy for dry eye disease

July 26, 1999

FDA approves same-day, second-eye treatment with Sunrise LTK system

July 15, 1999

More on PEDF: protein also has ophthalmic indications

July 13, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...